(Q38056972)

27 August 2017

title

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies (English)

1 reference

27 August 2017

Anant Sharma

1

1 reference

27 August 2017

Sachin R Shah

series ordinal

2

1 reference

27 August 2017

Henrik Illum

series ordinal

3

1 reference

27 August 2017

Jonathan Dowell

series ordinal

4

1 reference

27 August 2017

publication date

1 December 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

17

1 reference

27 August 2017

page(s)

2207-2222

1 reference

Final version of 2009 AJCC melanoma staging and classification

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

MAP kinase signalling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Assessment of CYP1A2 activity in clinical practice: why, how, and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Vemurafenib for melanoma metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

BRAF inhibition in refractory hairy-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640870-000000000-00000

Ultraviolet A and photosensitivity during vemurafenib therapy

21 January 2018

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

1 reference

12 December 2020

Ras mutations in human melanoma: a marker of malignant progression

1 reference

12 December 2020

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

Targeting RAS signalling pathways in cancer therapy

1 reference

12 December 2020

Loss of PTEN promotes tumor development in malignant melanoma

1 reference

12 December 2020

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

1 reference

12 December 2020

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

12 December 2020

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

12 December 2020

Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma

1 reference

12 December 2020

10.2165/11640870-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1022398218

0 references

1 reference